Integra LifeSciences reports Q3 2026 results, cites $7 M flood hit, completes $2.1 B refinancing and trims Q4 outlook
Integra LifeSciences (IART) posted third‑quarter 2026 revenue of $411.2 million, up 2.3% year‑over‑year, but disclosed an approximately $7 million revenue reduction from flood damage at its Cincinnati facility. Adjusted earnings per share were $0.59, while GAAP EPS was $0.19. The company completed a $2.1 billion debt refinancing after quarter‑end and lowered its fourth‑quarter revenue guidance to $413 million‑$433 million, reflecting ongoing Cincinnati recovery and softness in the Tissue Reconstruction segment.
Why it matters
The revised Q4 revenue range and the $30 million reduction in the full‑year revenue midpoint signal a modest top‑line shortfall for investors, while the refinancing adds roughly $8 million of interest expense in Q4, affecting near‑term cash flow (the company said).
Key facts
- 1Q3 2026 revenue was $411.2 million, a 2.3% increase on a reported basis. stocktitan.net
- 2The results included an approximate $7 million revenue impact from flood damage at the Cincinnati facility. stocktitan.net
- 3Adjusted EPS for the quarter was $0.59; GAAP EPS was $0.19. stocktitan.net
- 4Integra completed a $2.1 billion debt refinancing on October 19, 2026, extending maturities and enhancing financial flexibility. stocktitan.net
- 5Fourth‑quarter 2026 revenue guidance was lowered to a range of $413 million‑$433 million. gurufocus.com
- 6Full‑year 2026 revenue guidance was set at $1.634 billion‑$1.654 billion, down $30 million at the midpoint from prior guidance. finance.yahoo.com
Summary written by AlphAI AI Desk from 20 of 23 sources. Not investment advice. Figures are as stated by the linked sources.